Alpha 2.0
Login Register
» Authors » Jan Paul de Boer

Jan Paul de Boer

Explore the profile of Jan Paul de Boer including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 67
Citations 2185
Followers 0
Related Specialties
Oncology
General Surgery
Radiology
Top 10 Co-Authors
Flora E van Leeuwen
Charlotte L Zuur
Daphne de Jong
Alfons J M Balm
Abrahim Al-Mamgani
Berthe M P Aleman
Michael Hauptmann
Coen R N Rasch
Pieternella J Lugtenburg
Arash Navran
Published In
Head Neck
Blood
Radiother Oncol
J Clin Oncol
Nat Commun
Affiliations
Soon will be listed here.
Recent Articles
31.
Incidence of contralateral regional failure in the electively irradiated contralateral neck of patients with head and neck squamous cell carcinoma
de Veij Mestdagh P, van Werkhoven E, Navran A, de Boer J, Schreuder W, Vogel W, et al.
Clin Transl Radiat Oncol . 2019 May; 17:7-13. PMID: 31061901
Background: The vast majority of patients with head and neck squamous cell carcinoma (HNSCC) routinely undergo elective nodal irradiation (ENI) to both sides of the neck. Little is known about...
32.
The Dutch Breast Implant Registry: Registration of Breast Implant-Associated Anaplastic Large Cell Lymphoma-A Proof of Concept
Becherer B, de Boer M, Spronk P, Bruggink A, de Boer J, van Leeuwen F, et al.
Plast Reconstr Surg . 2019 Apr; 143(5):1298-1306. PMID: 31033810
Background: The Dutch Breast Implant Registry (DBIR) was established in April of 2015 and currently contains information on 38,000 implants in 18,000 women. As a clinical registry, it evaluates the...
33.
High prevalence of advanced colorectal neoplasia and serrated polyposis syndrome in Hodgkin lymphoma survivors
Rigter L, Spaander M, Aleman B, Bisseling T, Moons L, Cats A, et al.
Cancer . 2018 Dec; 125(6):990-999. PMID: 30561773
Background: Hodgkin lymphoma (HL) survivors treated with abdominal radiotherapy and/or alkylating chemotherapy have an increased risk of colorectal cancer (CRC). This study was aimed at evaluating the prevalence of colorectal...
34.
HLA class II expression on tumor cells and low numbers of tumor-associated macrophages predict clinical outcome in oropharyngeal cancer
Cioni B, Jordanova E, Hooijberg E, van der Linden R, de Menezes R, Tan K, et al.
Head Neck . 2018 Dec; 41(2):463-478. PMID: 30549362
Background: Human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma (OPSCC) is a highly immunogenic tumor and differences in tumor microenvironment might contribute to the improved survival of HPV-positive OPSCC patient. Methods:...
35.
Loss of androgen receptor signaling in prostate cancer-associated fibroblasts (CAFs) promotes CCL2- and CXCL8-mediated cancer cell migration
Cioni B, Nevedomskaya E, Melis M, van Burgsteden J, Stelloo S, Hodel E, et al.
Mol Oncol . 2018 May; 12(8):1308-1323. PMID: 29808619
Fibroblasts are abundantly present in the prostate tumor microenvironment (TME), including cancer-associated fibroblasts (CAFs) which play a key role in cancer development. Androgen receptor (AR) signaling is the main driver...
36.
A predictive model for residual disease after (chemo) radiotherapy in oropharyngeal carcinoma: Combined radiological and clinical evaluation of tumor response
Gouw Z, Jasperse B, Sonke J, Heemsbergen W, Navran A, Hamming-Vrieze O, et al.
Clin Transl Radiat Oncol . 2018 Mar; 6:1-6. PMID: 29594216
Background And Purpose: Early detection of Residual disease (RD) is vital for salvage possibilities after (chemo) radiatiotherapy for oropharyngeal carcinoma (OPC). We standardized clinical investigation to test its added value...
37.
Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial
Armand P, Engert A, Younes A, Fanale M, Santoro A, Zinzani P, et al.
J Clin Oncol . 2018 Mar; 36(14):1428-1439. PMID: 29584546
Purpose Genetic alterations causing overexpression of programmed death-1 ligands are near universal in classic Hodgkin lymphoma (cHL). Nivolumab, a programmed death-1 checkpoint inhibitor, demonstrated efficacy in relapsed/refractory cHL after autologous...
38.
Baseline peripheral blood leukocytosis: Biological marker predicts outcome in oropharyngeal cancer, regardless of HPV-status
Gouw Z, de Boer J, Navran A, van den Brekel M, Sonke J, Al-Mamgani A
Oral Oncol . 2018 Mar; 78:200-206. PMID: 29496051
Objectives: To study the prognostic value of abnormalities in baseline complete blood count in patients with oropharyngeal cancer (OPC) treated with (chemo) radiation. Methods And Materials: The prognostic value of...
39.
Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma
Roemer M, Redd R, Cader F, Pak C, Abdelrahman S, Ouyang J, et al.
J Clin Oncol . 2018 Feb; 36(10):942-950. PMID: 29394125
Purpose Hodgkin Reed-Sternberg (HRS) cells evade antitumor immunity by multiple means, including gains of 9p24.1/ CD274(PD-L1)/ PDCD1LG2(PD-L2) and perturbed antigen presentation. Programmed death 1 (PD-1) receptor blockade is active in...
40.
Breast Implants and the Risk of Anaplastic Large-Cell Lymphoma in the Breast
de Boer M, van Leeuwen F, Hauptmann M, Overbeek L, de Boer J, Hijmering N, et al.
JAMA Oncol . 2018 Jan; 4(3):335-341. PMID: 29302687
Importance: Breast implants are among the most commonly used medical devices. Since 2008, the number of women with breast implants diagnosed with anaplastic large-cell lymphoma in the breast (breast-ALCL) has...